AstraZeneca Phase III EMERALD-3 trial showed meaningful improvement in endpoint

Positive high-level results from the EMERALD-3 Phase III trial showed AstraZeneca’s (AZN) Imfinzi in combination with Imjudo, lenvatinib and transarterial chemoembolisation, TACE, demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival, PFS, versus TACE alone for patients with unresectable hepatocellular carcinoma, HCC, eligible for embolisation. At this interim analysis for overall survival, OS, a key secondary endpoint, this combination also demonstrated a trend toward OS improvement versus TACE alone. Patients in the investigational arms were treated with the STRIDE regimen, with or without lenvatinib, before TACE, and then alongside TACE.